Brokerages Set Oculis Holding AG (NASDAQ:OCS) Price Target at $29.14

Oculis Holding AG (NASDAQ:OCS) has earned an average recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $29.14.

A number of research firms recently commented on OCS. Robert W. Baird lowered their price objective on shares of Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 19th. Wedbush reissued an “outperform” rating and issued a $29.00 price objective on shares of Oculis in a research note on Wednesday, March 6th. Chardan Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Oculis in a research note on Tuesday, March 19th. Finally, HC Wainwright dropped their price target on shares of Oculis from $29.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, April 24th.

Institutional Investors Weigh In On Oculis

Several hedge funds have recently modified their holdings of the stock. abrdn plc purchased a new position in Oculis during the 4th quarter worth approximately $15,980,000. Compagnie Lombard Odier SCmA raised its position in Oculis by 47.3% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after buying an additional 30,750 shares during the period. Searle & CO. purchased a new stake in Oculis in the 4th quarter worth about $112,000. Finally, Wolverine Asset Management LLC acquired a new stake in Oculis during the 3rd quarter worth about $77,000. 22.30% of the stock is owned by hedge funds and other institutional investors.

Oculis Trading Down 0.7 %

Shares of Oculis stock opened at $12.71 on Friday. Oculis has a 1-year low of $9.05 and a 1-year high of $14.50. The business’s fifty day moving average price is $11.89 and its two-hundred day moving average price is $11.34. The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.04. The company had revenue of $0.21 million during the quarter, compared to analyst estimates of $0.28 million. As a group, equities research analysts anticipate that Oculis will post -1.72 EPS for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.